Trial Profile
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary) ; Azacitidine; Decitabine
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms INSPIRE
- Sponsors Onconova Therapeutics
- 22 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 05 Oct 2021 This trial has been completed in Sweden, according to European Clinical Trials Database. (2021-08-23)
- 05 Oct 2021 This trial has been discontinued in Poland, according to European Clinical Trials Database.